The immunobiological properties of a recombinant SRV-1 envelope protein and a neutralizing monoclonal antibody directed against it.

Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

The immunobiological properties of a recombinant SRV-1 envelope protein and a neutralizing monoclonal antibody directed against it.

Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:58 (abstract no. 42). Unique Identifier : AIDSLINE PRIM8/900042
Werner LL; Torres JV; Kwang HS; Leung CY; Benjamini E; Department of Clinical Pathology, School of Veterinary Medicine,; and Department of Medical Microbiology and Immunology, School of; Medicine, University of California, Davis, CA

Abstract: A synthetic peptide representing residues 142-167 contains a unique envelope region of the Simian (Type D) Retrovirus serotype 1 (SRV-1) and constitutes an antigenic site for the binding of murine and rhesus neutralizing antibodies to the SRV-1 strain. A murine monoclonal antibody, C11B8, produced by immunizing with an SRV-1 recombinant envelope protein (rEP), binds to SRV-1 142-167 and neutralizes SRV-1 infection in vitro. C11B8 antibody binds to the gp70 component of the SRV-1 envelope by Western blot analysis, and to both SRV-1 and SRV-2 on ELISA assay, yet shows strain-specificity in the capacity to neutralize SRV-1 but not SRV-2 or other stains tested. The SRV-1 rEP inhibits the neutralizing activity of C11B8 antibody for SRV-1 infection in vitro, but has no inhibitory effect on rhesus neutralizing antibodies to SRV-2. In addition, SRV-1 rEP shows the capacity to compete with SRV-1 (but not with SRV-2) by inhibiting its infectivity in vitro. These findings provide evidence that SRV-1 rEP both binds the site for SRV-1 attachment within the cell receptor and contains an epitope (residues 142-167) to which neutralizing antibodies are directed and which can induce a neutralizing antibody response. Whether or not this neutralizable epitope constitutes the binding site of the virus to the cell receptor remains to be ascertained. It seems clear, however, that immunity conferred at the level of neutralizing antibodies to SRV infection is strain-specific and involves the recognition of unique envelope sequences among the different viral strains.

Keywords: Animal Antibodies, Monoclonal/*IMMUNOLOGY Binding, Competitive Blotting, Western Epitopes/IMMUNOLOGY Macaca mulatta Neutralization Tests Receptors, Virus/*IMMUNOLOGY Recombinant Proteins/IMMUNOLOGY Retroviruses Type D, Simian/*IMMUNOLOGY Simian Acquired Immunodeficiency Syndrome/*IMMUNOLOGY Viral Envelope Proteins/*IMMUNOLOGY ABSTRACT
910730
M9170952

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .